Literature DB >> 34414289

Trends in incidence of oral anticoagulant-related intracerebral hemorrhage and sales of oral anticoagulants in Capital Region of Denmark 2010-2017.

Josefine Grundtvig1, Christian Ovesen1, Inger Havsteen2, Thomas Christensen3, David Gaist4,5, Helle K Iversen6, Christina Kruuse7, Alexander Lilja-Cyron8, Karen Ægidius1, Sverre Rosenbaum1, Per Meden1, Jacob Marstrand1, Louisa Christensen1, Thorsten Steiner9,10, Hanne Christensen1.   

Abstract

INTRODUCTION: Non-vitamin K-antagonist oral anticoagulants (NOAC) have become first choice oral anticoagulant (OAC) with decreasing use of vitamin K antagonists (VKA), partly due to lower risk of intracerebral hemorrhage (ICH). Aim: to identify trends in sale of OACs and relate them to trends in OAC-related ICH (OAC-ICH). PATIENTS AND METHODS: Study was based on the population in the Capital Region of Denmark (1.8 million inhabitants). We identified all patients admitted with a non-traumatic OAC-ICH in 2010-2017 and ascertained diagnosis and drug use through medical charts. We used information available in the public domain on sale of defined daily doses (DDD) of OAC in the Capital Region of Denmark.
RESULTS: 453 patients with OAC-ICH out of a total of 2877 ICH-events were identified. From 2010 to 2017 sale of NOAC rose from 0.1 to 11.8 DDD/1000 inhabitants/day (p < 0.001); while VKA sale decreased from 7.6 to 5.2 DDD/1000 inhabitants/day (p < 0.001). The total number of ICH events was stable between 2010 and 2017, but the proportion of OAC-ICH events increased from 13% in 2010 to 22% in 2017 (p < 0.001). The proportion of ICH events related to NOAC had a significant increasing trend (p < 0.001), whereas a decreasing trend was observed for VKA (p = 0.04). DISCUSSION: In Denmark, the population on OACs has increased; resulting from increased use of NOACs. Parallel to this development, the proportion of OAC-ICH overall has increased based on an increasing trend in NOAC-related ICH.
CONCLUSION: Our findings document a need for further research on prevention and treatment of this complication. © European Stroke Organisation 2021.

Entities:  

Keywords:  Non-vitamin K-antagonist oral anticoagulants; direct oral anticoagulants; hemorrhagic stroke; intracerebral hemorrhage; new oral anticoagulants; vitamin K-antagonists

Year:  2021        PMID: 34414289      PMCID: PMC8370066          DOI: 10.1177/23969873211008770

Source DB:  PubMed          Journal:  Eur Stroke J        ISSN: 2396-9873


  36 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Oral rivaroxaban for symptomatic venous thromboembolism.

Authors:  Rupert Bauersachs; Scott D Berkowitz; Benjamin Brenner; Harry R Buller; Hervé Decousus; Alex S Gallus; Anthonie W Lensing; Frank Misselwitz; Martin H Prins; Gary E Raskob; Annelise Segers; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Henri Bounameaux; Alexander Cohen; Bruce L Davidson; Franco Piovella; Sebastian Schellong
Journal:  N Engl J Med       Date:  2010-12-03       Impact factor: 91.245

Review 3.  Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage.

Authors:  Georgios Tsivgoulis; Vasileios-Arsenios Lioutas; Panayiotis Varelas; Aristeidis H Katsanos; Nitin Goyal; Robert Mikulik; Kristian Barlinn; Christos Krogias; Vijay K Sharma; Konstantinos Vadikolias; Efthymios Dardiotis; Theodore Karapanayiotides; Alexandra Pappa; Christina Zompola; Sokratis Triantafyllou; Odysseas Kargiotis; Michael Ioakeimidis; Sotirios Giannopoulos; Ali Kerro; Argyrios Tsantes; Chandan Mehta; Mathew Jones; Christoph Schroeder; Casey Norton; Anastasios Bonakis; Jason Chang; Anne W Alexandrov; Panayiotis Mitsias; Andrei V Alexandrov
Journal:  Neurology       Date:  2017-08-16       Impact factor: 9.910

4.  Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis.

Authors:  Gregoire Boulouis; Andrea Morotti; Marco Pasi; Joshua N Goldstein; M Edip Gurol; Andreas Charidimou
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-13       Impact factor: 10.154

5.  Clinical Outcomes and Neuroimaging Profiles in Nondisabled Patients With Anticoagulant-Related Intracerebral Hemorrhage.

Authors:  Vasileios-Arsenios Lioutas; Nitin Goyal; Aristeidis H Katsanos; Christos Krogias; Ramin Zand; Vijay K Sharma; Panayiotis Varelas; Konark Malhotra; Maurizio Paciaroni; Aboubakar Sharaf; Jason Chang; Theodore Karapanayiotides; Odysseas Kargiotis; Alexandra Pappa; Jeffrey Mai; Abhi Pandhi; Christoph Schroeder; Argyrios Tsantes; Chandan Mehta; Ali Kerro; Ayesha Khan; Panayiotis D Mitsias; Magdy H Selim; Andrei V Alexandrov; Georgios Tsivgoulis
Journal:  Stroke       Date:  2018-10       Impact factor: 7.914

6.  Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant type.

Authors:  Duncan Wilson; Andreas Charidimou; Clare Shakeshaft; Gareth Ambler; Mark White; Hannah Cohen; Tarek Yousry; Rustam Al-Shahi Salman; Gregory Y H Lip; Martin M Brown; Hans Rolf Jäger; David J Werring
Journal:  Neurology       Date:  2015-12-30       Impact factor: 9.910

Review 7.  Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis.

Authors:  Manuj Sharma; Victoria R Cornelius; Jignesh P Patel; J Graham Davies; Mariam Molokhia
Journal:  Circulation       Date:  2015-05-20       Impact factor: 29.690

Review 8.  The Danish Stroke Registry.

Authors:  Søren Paaske Johnsen; Annette Ingeman; Heidi Holmager Hundborg; Susanne Zielke Schaarup; Jesper Gyllenborg
Journal:  Clin Epidemiol       Date:  2016-10-25       Impact factor: 4.790

Review 9.  Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010.

Authors:  Rita V Krishnamurthi; Valery L Feigin; Mohammad H Forouzanfar; George A Mensah; Myles Connor; Derrick A Bennett; Andrew E Moran; Ralph L Sacco; Laurie M Anderson; Thomas Truelsen; Martin O'Donnell; Narayanaswamy Venketasubramanian; Suzanne Barker-Collo; Carlene M M Lawes; Wenzhi Wang; Yukito Shinohara; Emma Witt; Majid Ezzati; Mohsen Naghavi; Christopher Murray
Journal:  Lancet Glob Health       Date:  2013-10-24       Impact factor: 26.763

10.  Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry.

Authors:  Patricia N Apenteng; Haiyan Gao; Fd Richard Hobbs; David A Fitzmaurice
Journal:  BMJ Open       Date:  2018-01-13       Impact factor: 2.692

View more
  3 in total

1.  Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation.

Authors:  Naja E Vinding; Søren L Kristensen; Rasmus Rørth; Jawad H Butt; Lauge Østergaard; Jonas B Olesen; Christian Torp-Pedersen; Gunnar H Gislason; Lars Køber; Christina Kruuse; Søren P Johnsen; Emil L Fosbøl
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

2.  Sex-Differences in Oral Anticoagulant-Related Intracerebral Hemorrhage.

Authors:  Josefine Grundtvig; Christian Ovesen; Thorsten Steiner; Cheryl Carcel; David Gaist; Louisa Christensen; Jacob Marstrand; Per Meden; Sverre Rosenbaum; Helle K Iversen; Christina Kruuse; Thomas Christensen; Karen Ægidius; Inger Havsteen; Hanne Christensen
Journal:  Front Neurol       Date:  2022-03-03       Impact factor: 4.003

3.  Decrease in incidence of oral anticoagulant-related intracerebral hemorrhage over the past decade in the Netherlands.

Authors:  Michaël Tj Peeters; Florence Vroman; Tobien Ahcml Schreuder; Robert J van Oostenbrugge; Julie Staals
Journal:  Eur Stroke J       Date:  2022-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.